The NIH BRAIN Initiative supports first in human, U.S. Food and Drug Administration (FDA) regulated clinical trials of novel invasive and non-invasive technologies to address disorders of the central nervous system, including neurological, neuropsychiatric, and sensory conditions. These investigational trials must also address circuit level activation of the central nervous system and typically involve closed-loop sensing and stimulating technology. Conditions under investigation include Parkinson’s disease, epilepsy, depression, stroke, tremor, visual loss, deafness, and paralysis, among others.
Through the research approaches outlined below, the NIH BRAIN Initiative aims to promote a better understanding of how the brain thinks, computes, perceives and motivates overt and covert behavior.
Funding Opportunities
BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional) [RFA-NS-24-016]
BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional) [RFA-NS-24-017]
Contact
Yvonne Bennett, Ph.D.
National Institute of Mental Health (NIMH)
yvonne.bennett@nih.gov
Megan Frankowski, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
megan.frankowski@nih.gov